Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs Zimmer Biomet Holdings Inc — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $48.82 (market cap $3.14B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 5.4× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 High Div Low Volatility ETF for 125 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SPHD | ZBH | |
|---|---|---|
Market Cap | $3.14B | $16.95B |
Volume | 1,461,349 | 2,505,240 |
52-Week High | $53.55 | $103.98 |
52-Week Low | $46.96 | $79.58 |
Typical Hold Time | 125 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $48.82, up 1.31% today, but technical indicators show a bearish trend with 17 sell signals versus 4 buy signals. The ETF's moving averages are unanimously bearish while oscillators remain neutral. Recent dividend payments of $0.20 and $0.21 demonstrate its income focus, though financial ratios are unavailable in the current data.
The outlook remains cautious given the bearish technical picture and mixed sentiment. While SPHD offers monthly dividend convenience for income investors, concerns about total return performance versus peers like SCHD present risks. Market volatility and yield sustainability are key considerations for potential investors.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
